Clinical trial

Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BEfindLichkeitsverbesserung Unter CANnabinoid-ExtrakTen Bei Onkologischen Patienten)

Name
BELCANTO
Description
The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.
Trial arms
Trial start
2023-12-01
Estimated PCD
2026-11-30
Trial end
2026-11-30
Status
Not yet recruiting
Phase
Early phase I
Treatment
Cannabisextrakt Avextra 10/10 Lösung
medical cannabinoids
Arms:
Cannabisextrakt Avextra 10/10 Lösung, Placebo
Size
170
Primary endpoint
ESAS-TSDS score
12 days
Eligibility criteria
Inclusion Criteria: * ≥25 years old and legally competent * Palliative oncological therapy * ECOG status 1, 2 or 3, incapacitated for work * ESAS TSDS \> 15 * Nutritional Risk Screening \> 3 * Pain numerical rating scale \> 3 * informed consent * for WOCBP: * Negative pregnancy test * Reliable contraception (Pearl Index \< 1%) Exclusion Criteria: * nausea/vomiting * Inability to understand and complete the questionnaires * Cannabis use in the last 2 years * Alcohol addiction * Pregnancy/lactation * Contraindications or intolerance to the study medication * Simultaneous participation in other clinical studies * Any other condition as judged by the investigator, e.g. non-compliance
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Multi-center, prospective, interventional, randomized, two-arm, placebo-controlled, parallel, double-blinded clinical trial according to German Drug Law (AMG)/GCP and German Narcotic Drugs Act (BtMG)', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'IMPs are centrally blinded and randomised at the pharmacy.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 170, 'type': 'ESTIMATED'}}
Updated at
2023-10-24

1 organization

1 product

4 indications

Indication
Cancer
Indication
Palliative Care
Indication
Quality of Life
Indication
Cannabinoids